<DOC>
	<DOCNO>NCT02182557</DOCNO>
	<brief_summary>Study investigate safety efficacy WAL 801 CL Dry Syrup pruritus associate paediatric atopic dermatitis comparison Ketotifen Fumarate Dry Syrup confirm appropriateness dosage WAL801 Dry Syrup .</brief_summary>
	<brief_title>WAL 801 CL Dry Syrup Paediatric Atopic Dermatitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<mesh_term>Epinastine</mesh_term>
	<criteria>For inclusion study , patient must pediatric atopic dermatitis patient meet follow criterion thus appropriate observation pruritus . Diagnosis atopic dermatitis conduct accordance `` Definition Diagnostic Criteria Atopic Dermatitis '' issue Japanese Dermatological Association . 15 year age young Body weight 14 kg Outpatients One week longer pass since patient start use external steroid preparation `` Strong '' low grade , stop use external steroid preparation , time obtainment consent patient Pruritus `` 2 '' high grade , immediately initial administration Use sustain release adrenocorticotropic hormone ( Kenacort® A , Depomedrol® , etc . ) , oral preparation methotrexate , oral preparation ciclosporin , within 4 week initial administration investigational product Oral intake , inhalation injection steroid within 2 week initial administration investigational product Use external steroid preparation `` Very Strong '' high grade site face scalp within 2 week initial administration investigational product Undergoing phototherapy Undergoing specific desensitization therapy modulation therapy Past history contact dermatitis cause external steroid preparation Possibility exacerbation external steroid preparation infectious skin disease cause bacteria , fungi , virus Present past history convulsive disorder , epilepsy ( convulsion threshold value may lower reference drug , Ketotifen Fumarate ) Clinically significant hepatic , renal , cardiac disease complication : therefore , judgement patient ineligible inclusion study ( Please note patient must exclude study patient fell Grade 2 , MHW ( Ministry health welfare ) Adverse Reaction Severity Classification Criteria . ) Past history allergy drug Participation clinical study , history participation clinical study within 6 month date patient give consent participate study Judgement Principal Investigator Investigator patient ineligible inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>